Remove Laboratories Remove RNA Remove Vaccine
article thumbnail

The Long Road to End Tuberculosis

Codon

Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB. These breakthroughs have significantly curbed cases, with vaccination reducing the odds of death by 74 percent. tuberculosis , to develop the vaccine.

article thumbnail

Levers for Biological Progress

Codon

” Nobody really knows without trying it out in the laboratory. Scientists are already building a model that can, for example, look at which RNA molecules are expressed in a cell at t=0 and predict how those molecules will change at t=1. But these models will become increasingly sophisticated over time. There are a few reasons.

DNA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Discovery and development of COVID?19 vaccine from laboratory to clinic

Chemical Biology and Drug Design

Challenges involved in vaccines formulation were also featured. Use of computational methods and models for vaccine development has revolutionized the traditional methods of vaccine development. Main role of mRNA vaccines in the COVID-19 challenge was discussed.

article thumbnail

F. William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines

Broad Institute

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines By Corie Lok October 16, 2024 Breadcrumb Home F. William Studier for development of widely used protein- and RNA-production platform F. Merkin (left) and F.

article thumbnail

PRAC investigates heart inflammation reports with Pfizer vaccine

The Pharma Data

During an early May meeting, the European Medicines Agency’s safety committee concluded two reviews of safety signals related to COVID-19 vaccines, while it continued following other vaccine-related “topics of interest.” These included reports of heart muscle inflammation after receipt of the Pfizer-BioNTech vaccine. .

article thumbnail

Johnson & Johnson’s One-Dose COVID Vaccine Promising in Early Trial

The Pharma Data

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The new vaccine remains stable for a time in the refrigerator. WEDNESDAY, Jan. 13 in the New England Journal of Medicine.

article thumbnail

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

The Pharma Data

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. The majority of adverse events were mild or moderate in severity.